Filing Details
- Accession Number:
- 0000874716-24-000014
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-09 17:00:48
- Reporting Period:
- 2024-02-07
- Accepted Time:
- 2024-02-09 17:00:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1556270 | Jay Jonathan Mazelsky | One Idexx Drive Westbrook ME 04092 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-02-07 | 12,000 | $67.85 | 91,247 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-02-07 | 5,356 | $571.71 | 85,891 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-07 | 4,124 | $572.53 | 81,767 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-07 | 462 | $573.19 | 81,305 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-07 | 1,353 | $574.75 | 79,952 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-02-07 | 705 | $575.48 | 79,247 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right-to-buy) | Disposition | 2024-02-07 | 12,000 | $0.00 | 12,000 | $67.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 29,260 | 2026-02-13 | No | 4 | M | Direct |
Footnotes
- Includes 13.247 shares purchased under the Issuer Employee Stock Purchase Plan on December 29, 2023.
- Represents the weighted average price of the shares sold ranging from a low of $571.12 to a high of $572.11 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $572.13 to a high of $573.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $573.14 to a high of $573.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $574.29 to a high of $575.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Represents the weighted average price of the shares sold ranging from a low of $575.35 to a high of $575.65 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- Grant of option to buy shares of Issuer common stock that became exercisable in four annual installments beginning February 14, 2017.
- Not applicable.
Billionaire Hedge Funds
